{"nctId":"NCT03096834","briefTitle":"A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies","startDateStruct":{"date":"2017-03-20","type":"ACTUAL"},"conditions":["Episodic Migraine"],"count":246,"armGroups":[{"label":"Placebo DB","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo Pre-Filled Syringe (PFS)"]},{"label":"AMG334 140 mg DB","type":"EXPERIMENTAL","interventionNames":["Biological: AMG334 (70 mg) Pre-Filled Syringe (PFS)"]},{"label":"AMG334 140 mg DB cont on AMG334 140 mg","type":"EXPERIMENTAL","interventionNames":["Biological: AMG334 (70 mg) Pre-Filled Syringe (PFS)"]},{"label":"Placebo in DB to AMG334 140 mg","type":"EXPERIMENTAL","interventionNames":["Biological: AMG334 (70 mg) Pre-Filled Syringe (PFS)"]}],"interventions":[{"name":"AMG334 (70 mg) Pre-Filled Syringe (PFS)","otherNames":[]},{"name":"Placebo Pre-Filled Syringe (PFS)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented history of migraine in the 12 months prior to screen\n* 4-14 days per month of migraine symptoms\n* \\>=80% diary compliance during the Baseline period\n* Failure of previous migraine prophylactic treatments\n\nExclusion Criteria:\n\n* \\>50 years old at migraine onset\n* Pregnant or nursing\n* History of cluster or hemiplegic headache\n* Evidence of seizure or psychiatric disorder\n* Score of over 19 on Beck Depression Inventory-2\n* Active chronic pain syndrome\n* Cardiac or hepatic disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least 50% Reduction From Baseline of Monthly Migraine Days (MMD) in the Last Month (Last 4 Weeks of Treatment)","description":"A migraine day was defined as any calendar day in which the subject experienced a qualified migraine headache defined as: with/without aura, lasting ≥ 30 minutes with at least 1 criteria: 1. ≥ 2 of following pain features: unilateral, throbbing, moderate to severe or exacerbated with exercise/physical activity, 2. ≥ 1 of the following symptoms: nausea and/or vomiting, photophobia and phonophobia. If a migraine-specific medication (ie, triptan or ergotamine) was taken during aura, or a headache, it was counted as a migraine day regardless of duration and pain features/associated symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null},{"groupId":"OG001","value":"13.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Monthly Migraine Days (MMD) in the Last Month (Last 4 Weeks of Treatment)","description":"A migraine day was defined as any calendar day in which the subject experienced a qualified migraine headache defined as: with/without aura, lasting ≥ 30 minutes with at least 1 criteria: 1. ≥ 2 of following pain features: unilateral, throbbing, moderate to severe or exacerbated with exercise/physical activity, 2. ≥ 1 of the following symptoms: nausea and/or vomiting, photophobia and phonophobia. If a migraine-specific medication (ie, triptan or ergotamine) was taken during aura, or a headache, it was counted as a migraine day regardless of duration and pain features/associated symptoms.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.75","spread":"0.43"},{"groupId":"OG001","value":"-0.16","spread":"0.41"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Physical Impairment and Everyday Activities as Measured by the Migraine Physical Function Impact Diary (MPFID) at Month 3","description":"MPFID has 2 domains: Everyday Activities, which consisted of 7 items and Physical Impairment with 5 items using a 5-point scale. Scores were summed across each domain and were then transformed and used for analyses. Transforming MPFID domain scores ranged from 0-100, where higher scores were indicative of greater migraine impact (ie, higher burden)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.85","spread":"0.84"},{"groupId":"OG001","value":"1.61","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.36","spread":"0.83"},{"groupId":"OG001","value":"0.55","spread":"0.81"}]}]}]},{"type":"SECONDARY","title":"Change in the Number of Monthly Acute Migraine-specific Medication Treatment Days at Month 3","description":"Number of days on which acute migraine-specific medications were used were recorded in eDiary between each monthly IP dose. Migraine-Specific medications included two categories of medications: triptan-based migraine medications and ergotamine-based migraine medications. Monthly migraine-specific medication use at baseline was the number of migraine-specific medication treatment days in the baseline period.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.25","spread":"0.24"},{"groupId":"OG001","value":"0.46","spread":"0.28"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a 75% Reduction From Baseline of Monthly Migraine Days (MMD) in the Last Month (Last 4 Weeks of Treatment)","description":"A migraine day was defined as any calendar day in which the subject experienced a qualified migraine headache defined as: with/without aura, lasting ≥ 30 minutes with at least 1 criteria: 1. ≥ 2 of following pain features: unilateral, throbbing, moderate to severe or exacerbated with exercise/physical activity, 2. ≥ 1 of the following symptoms: nausea and/or vomiting, photophobia and phonophobia. If a migraine-specific medication (ie, triptan or ergotamine) was taken during aura, or a headache, it was counted as a migraine day regardless of duration and pain features/associated symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a 100% Reduction From Baseline of Monthly Migraine Days (MMD) in the Last Month (Last 4 Weeks of Treatment)","description":"A migraine day was defined as any calendar day in which the subject experienced a qualified migraine headache defined as: with/without aura, lasting ≥ 30 minutes with at least 1 criteria: 1. ≥ 2 of following pain features: unilateral, throbbing, moderate to severe or exacerbated with exercise/physical activity, 2. ≥ 1 of the following symptoms: nausea and/or vomiting, photophobia and phonophobia. If a migraine-specific medication (ie, triptan or ergotamine) was taken during aura, or a headache, it was counted as a migraine day regardless of duration and pain features/associated symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Developed Anti-AMG334 Antibodies","description":"Blood samples for immunogenicity testing were collected for the measurement of anti-AMG334 binding antibodies.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":119},"commonTop":["Nasopharyngitis","Influenza","Back pain","Injection site pain","Arthralgia"]}}}